Antifungal susceptibilities and identification of species of the Sporothrix schenckii complex isolated in Brazil

Journal of Music Therapy

Volumn 52, Issue 1, 2015, Pages 56-64

  Stopiglia, Cheila Denise Ottonelli ^a,b   Magagnin, Cibele Massotti ^a   Castrill, Mauricio Ramirez ^a   Mendes, Sandra Denise Camargo ^a,c   Heidrich, Daiane ^a   Valente, Patricia ^a   Scroferneker, Maria Lucia ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

^c EMPRESA DE PESQUISA AGROPECUÁRIA E EXTENSÃO RURAL DE SANTA CATARINA   (Brazil)

Author keywords

Antifungal agents; Sporothrix; Sporotrichosis

Indexed keywords

EID: 84898948328     PISSN: 00222917     EISSN: None     Source Type: Journal    
DOI: 10.3109/13693786.2013.818726     Document Type: Article

References (43)

1. Dixon DM, Salkin IF, Duncan RA et al. Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest U.S. epidemic of sporotri-chosis. J Clin Microbiol 1991; 29: 1106-1113.
2. Queiroz-Telles F, Nucci M, Colombo AL, Tobón A, Restrepo A. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol 2011; 49: 225-236.
3. da Rosa AC, Scroferneker ML, Vettorato R, Gervini RL, Vet-torato G, Weber A. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol 2005; 52: 451-459.
4. Landell MF, Stopiglia CD, Billodre RG et al. Evaluation of the origin of a sample of Sporothrix schenckii that caused contamination of a researcher in Southern Brazil. Mycopathologia 2011; 171: 203-207.
5. Sampaio SAP, Lacaz CS, Almeida F. Clinical aspects of sporotri-chosis in SP. Analysis of 235 cases. Rev Hosp Cĺi n 1954; 1: 391-402 [in Portuguese].
6. Galhardo MC, de Oliveira RM, Valle AC et al. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotri-chosis in Rio de Janeiro, Brazil. Med Mycol 2008; 46: 141-151.
7. Cooper CR, Breslin BJ, Dixon DM, Salkin IF. DNA typing of isolates associated with the 1988 sporotrichosis epidemic. J Clin Microbiol 1992; 30: 1631-1635.
8. Marimon R, Gené J, Cano J et al. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol 2006; 44: 3251-3256.
9. O'Reilly LC, Altman SA. Macrorestriction analysis of clinical and environmental isolates of Sporothrix schenckii. J Clin Mi-crobiol 2006; 44: 2547-2552.
10. Marimon R, Gené J, Cano J, Guarro J. Sporothrix luriei: a rare fungus from clinical origin. Med Mycol 2008; 46: 621-625.
11. Marimon R, Cano J, Gené J et al. Sporothrix brasiliensis, S. globosa and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol 2007; 45: 3198-3206.
12. de Meyer EM, de Beer ZW, Summerbell RC et al. Taxonomy and phylogeny of new wood-and soil-inhabiting Sporothrix species in the Ophiostoma stenoceras-Sporothrix schenckii complex. Mycologia 2008; 100: 647-661.
13. Madrid H, Gené J, Cano J, Silvera C, Guarro J. Sporothrix brun-neoviolacea and Sporothrix dimorphospora, two new members of the Ophiostoma stenoceras-Sporothrix schenckii complex. Mycologia 2010; 102: 1193-1203.
14. Coskun B, Saral Y, Akpolat N, Ataseven A, Cicek D. Sporotri-chosis successfully treated with terbinafine and potassio iodide: case report and review of the literature. Mycopathologia 2004; 158: 53-56.
15. Arechavala A, Orduna T, Maiolo E et al. Disseminated sporotri-chosis with cutaneous and visceral. Rev Patol Trop 2011; 40: 73-84 [in Spanish].
16. Kohler LM, Hamdan JS, Ferrari TC. Successful treatment of a disseminated Sporothrix schenckii infection and in vitro analysis for antifungal susceptibility testing. Diagn Microbiol Infect Dis 2007; 58: 117-120.
17. McGinnis MR, Nordoff N, Li RK, Pasarell L, Warnock DW. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol 2001; 39: 369-371.
18. Meinerz ARM, Nascente PS, Schuch LFD et al. In vitro susceptibility of isolates of Sporothrix schenckii to terbinafine and itraconazole. Rev Soc Bras Med Trop 2007; 40: 60-62 [in Portuguese].
19. Heidrich D, Stopiglia CDO, Senter L et al. Successful treatment of terbinafine in a case of sporotrichosis. An Bras Dermatol 2011; 86: S182-185.
20. Kohler LM, Soares BM, de Assis Santos D, Da Silva Barros ME, Hamdan JS. In vitro susceptibilities of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms. Can J Microbiol 2006; 52: 843-847.
21. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, approved standard, M38-A2, 2nd ed. Vilanova: Clinical and Laboratory Standards Institute, 2008.
22. Espinel-Ingroff A, Fothergill A, Meter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungici-dal concentrations to new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204-3208.
23. Oliveira MM, Almeida-Paes R, Muniz MM, Gutierrez-Galhardo MC, Zancope-Oliveira RM. Phenotypic and molecular identification of Sporothrix isolates from an epidemic area of sporotri-chosis in Brazil. Mycopathologia 2011; 172: 257-267.
24. Oliveira DC, Lopes PG, Spader TB et al. Antifungal susceptibilities of Sporothrix albicans, S. brasiliensis, and S. luriei of the S. schenckii complex identified in Brazil. J Clin Microbiol 2011; 49: 3047-3049.
25. Rodrigues AM, de Hoog S, de Camargo ZP. Emergence of pathogenicity in the Sporothrix schenckii complex. Med Mycol 2013; 51: 405-412.
26. Schubach A, Barros MB, Wanke B. Epidemic sporotrichosis. Curr Opin Infect Dis 2008; 21: 129-133.
27. Madrid H, Cano J, Gené J et al. Sporothrix globosa, a pathogenic fungus with widespread geographical distribution. Rev Iberoam Micol 2009; 26: 218-222.
28. Oliveira MME, Almeida-Paes R, Muniz MM et al. Sporotri-chosis caused by Sporothrix globosa in Rio de Janeiro, Brazil: case report. Mycopathologia 2010; 169: 359-363.
29. de Oliveira MM, Sampaio P, Almeida-Paes R et al. Rapid identification of Sporothrix species by T3B fingerprinting. J Clin Microbiol 2012; 50: 2159-2162.
30. Alvarado-Rodriguez E, Torres-Rodriguez JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother 2007; 51: 2420-2423.
31. Marimon R, Serena C, Gene J, Cano J. In vitro antifungal susceptibilities of five species of Sporothrix. Antimicrob Agents Chemother 2008; 52: 732-734.
32. Francesconi G, Francesconi do, Valle AC, Passos SL et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itra-conazole for the treatment of cutaneous sporotrichosis. Myco-pathologia 2011; 171: 349-354.
33. Chapman SW, Pappas P, Kauffman C et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine [500 and 1000 mg day(-1)] in the treatment of cutaneous or lympho-cutaneous sporotrichosis. Mycoses 2004; 47: 62-68.
34. Gutierrez-Galhardo MC, Zancopé-Oliveira RM, Monzón A, Rodriguez-Tudela JL, Cuenca-Estrella M. Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test. Mycoses 2010; 53: 227-231.
35. Kohler LM, Monteiro PCF, Hahn RC, Hamdan JS. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J Clin Microbiol 2004; 42: 4319-4320.
36. Silveira CP, Torres-Rodŕiguez JM, Alvarado-Ramirez E et al. MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii. J Med Microbiol 2009; 58: 1607-1610.
37. de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R et al. Treatment of cutaneous sporotrichosis with itraconazole-study of 645 patients. Clin Infect Dis 2011; 52: 200-206.
38. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002; 49: 7-10.
39. Chryssanthou E, Cuenca-Estrella M. Comparison of the antifun-gal susceptibility testing subcommittee of the European Committee on antibiotic susceptibility testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-3844.
40. Trilles L, Fernández-Torres B, Dos Santos Lazéra M et al. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother 2005; 49: 3952-3954.
41. Morera-López Y, Torres-Rodŕiguez JM, Jiménez-Cabello T. In vitro susceptibility of fungal and yeast clinical isolates to itra-conazole and voriconazole. Rev Iberoam Micol 2005; 22: 105-109.
42. Kauffman CA, Pappas PG, McKinsey DS et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22: 46-50.
43. Diaz M, Negroni R, Montero-Gei F et al. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immuno-competent host. Clin Infect Dis 1992; 14: 68-76.